期刊文献+

细胞及瘤块种植人前列腺癌裸鼠皮下移植瘤模型的比较 被引量:1

Comparison of subcutaneously xenografts model of human prostate cancer in nude mice established by cell suspension and tumor tissue
下载PDF
导出
摘要 目的比较细胞悬液法及瘤块法种植裸鼠前列腺癌皮下移植瘤,以期获得使瘤体生长最快,质量最佳的种植方式。方法采用细胞悬液及瘤块两种方式种植PC-3细胞人前列腺癌皮下移植瘤,比较两种种植方法所种植的移植瘤的成瘤率、成瘤潜伏期、瘤体形态以及移植瘤的中心坏死灶,同时对两种方法种植的皮下移植瘤进行常规病理学检查。本研究同时观察了PC-3细胞悬液浓度对于种植皮下移植瘤成瘤的影响。结果两种方式种植的移植瘤的成瘤率差异无统计学意义,采用瘤块种植的移植瘤生长较细胞种植稍快,瘤体形态各异,较容易发生中心性坏死;细胞悬液组成瘤稍慢,瘤体较规则,多呈圆形或椭圆形,发生中心性坏死较晚,而且随着细胞浓度增高,其成瘤潜伏期明显缩短。结论通过比较发现细胞悬液种植皮下移植瘤较瘤块种植更有优势,而且采用较高浓度细胞悬液种植可以有效缩短成瘤潜伏期,是一种较为理想的种植方式。 Objective To compare the different method of transplanting subcutaneously transplanted tumor in nude mice.Methods Xenograft models of human PC-3 prostate cancer in nude mice with cell suspension of different concentrations and tumor tissue were established,respectively.Then the time of tumor formation,take rates,morphological features and central tumor necrosis werecompared between the two groups.Meanwhile the histopathological features of transplanted tumor were examined,the tumor volume were measured,and the growth curve was drawn.Results No significant differences were observed in take rates in tumors established from the two types of implants.The xenograft of tumor tissue group formed in an earlier time,but the shape was irregular and central necrosis occured more easily.Though the xenograft of cell suspension group formed later than tumor tissue group,the shape was regular and central necrosis occurred late.There were no significant differences in the pathological features between the two groups.With the increase of concentrations of cells,the time of tumor formation was significantly shortened.Conclusion High concentration cell suspension is an ideal method to implant subcutaneously transplanted tumor of prostate cancer in nude mice.
出处 《海南医学》 CAS 2014年第2期157-160,共4页 Hainan Medical Journal
基金 国家自然科学基金(编号:81271597 81270208)
关键词 裸鼠 皮下移植瘤 前列腺癌PC-3细胞 瘤块 Nude mice Subcutaneously xenograft PC-3 human prostate cancer cells Tumor tissue
  • 相关文献

参考文献13

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CACancer J Clin, 2011,61(2): 69-90.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CACancer J Clin, 2012,62(1): 10-29.
  • 3Feng S, Agoulnik IU, Truong A, et al. Suppression of relaxin recep-tor RXFP1 decreases prostate cancer growth and metastasis [J]. En-docrRelat Cancer, 2010, 17(4): 1021-1033.
  • 4Jager W, Moskalev I, Janssen C, et al. Ultrasound-guided intramuralinoculation of orthotopic bladder cancer xenografts: a novelhigh-precision approach [J]. PLoS One, 2013,8(3): e59536.
  • 5萧云备,张晓威,牛屹东,等.前列腺癌动物模型[J].实验动物学,2010, 27(6): 55-58.
  • 6Naiki T,Asamoto M, Toyoda-Hokaiwado N,et al. Organ specificGst-pi expression of the metastatic androgen independent prostatecancer cells in nude mice [J]. Prostate, 2012, 72(5): 533-541.
  • 7Shen ZY, Shen E, Zhang JZ,et al. Effects of low-frequency ultra-sound and microbubbles on angiogenesis-associated proteins in sub-cutaneous tumors of nude mice [J]. Oncol Rep, 2013, 30(2):842-850.
  • 8王晓路,刘桂珍,黄立嵩,陈红岩,王东彬,张勇,黎玮.5-氮杂-2'-脱氧胞苷对人前列腺癌裸鼠移植瘤生长及雄激素受体表达影响的研究[J].实用癌症杂志,2012,27(1):4-8. 被引量:2
  • 9Guo CY, Wang XF, Xu KX, et al. Inhibitory effect of doxazosin onthe growth of transplanted tumor of prostate cancer ceil PC-3 innude mice [J]. Beijing Da Xue Xue Bao, 2005,37(3): 273-277.
  • 10Gray DR, Huss WJ, Yau JM, et al. Short-term human prostate prima-ry xenografts: an in vivo model of human prostate cancer vascula-ture and angiogenesis [J]. Cancer Res, 2004, 64(5): 1712-1721.

二级参考文献46

  • 1姚青,张建民.前列腺癌与相关基因DNA甲基化[J].实用癌症杂志,2004,19(5):547-549. 被引量:1
  • 2甘道举,江军,陈善勤,赖建平,王学华,孙广运,牟江洪.雄激素受体在雄激素非依赖性前列腺癌的表达[J].临床泌尿外科杂志,2006,21(4):279-281. 被引量:11
  • 3Momparler RL.Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine)[J].Seminars in Oncology,2005,32(5):443.
  • 4Ginzinger DG.Gene quantification using real-time quantitative PCR:an emerging technology hits the mainstream[J].Exp Hematol,2002,30(6):503.
  • 5Nelson WG,Yegnasubramanian S,Agoston AT,et al.Abnormal DNA methylation,epigenetics,and prostate cancer[J].Front Biosci,2007,12:4254.
  • 6Kantarjian HM,O'Brien S,Cortes J,et al.Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia[J].Cancer,2003,98(3):522.
  • 7Brueckner B,Kuck D,Lyko F.DNA methyltransferase inhibitors for cancer therapy[J].Cancer Journal,2007,13(1):17.
  • 8Thibault A,Figg WD,Bergan RC,et al.A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer[J].Tumori,1998,84(1):87.
  • 9Momparler RL,Ayoub J.Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer[J].Lung Cancer,2001,34 (Suppl 4):S111.
  • 10Buchanan G,Irvine RA,Coetzee GA,et al.Contribution ofthe androgen receptor to prostate cancer predisposition and progression[J].Cancer Metastasis Reviews,2001,20(3-4):207.

共引文献3

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部